Zdrowie i gospodarka · 28/07/2014

FDA Releases Guidance on 510(k) Program for Evaluating Substantial Equivalence in Premarket Notifications

The Food and Drug Administration (FDA) has made available a new guidance document detailing its review practices for 510(k) premarket notifications, providing clarity on the regulatory framework and policies underlying these submissions.